FOXP3 and neoplasm: The findings highlight the complexity of FoxP3+ Tregs function in various tumor stages, which may relate to the fact that Tregs mainly suppress pro-tumor inflammation in early stages of tumors, but hinder tumor killing by effector T cells in advanced stages.